MARKET

XBIT

XBIT

Xbiotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.47
-0.33
-5.69%
After Hours: 5.47 0 0.00% 16:00 05/24 EDT
OPEN
5.80
PREV CLOSE
5.80
HIGH
5.80
LOW
5.37
VOLUME
124.96K
TURNOVER
0
52 WEEK HIGH
18.46
52 WEEK LOW
5.37
MARKET CAP
166.50M
P/E (TTM)
-8.1593
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Monday
  On Monday, 198 companies reached new 52-week lows.
Benzinga · 05/16 17:59
Why Are XBiotech Shares Trading Higher Today
Benzinga · 04/28 18:53
OCN, NVIV and XBIT among mid-day movers
Gainers: Statera Biopharma (STAB) +132%. SQZ Biotechnologies (SQZ) +35%. RCM Technologies (RCMT) +24%. Integrated Media Technology (IMTE) +21%. Ocwen Financial (OCN) +21%. Pitney Bowes (PBI) +20%. Allego (ALLG) +18%. PTC (PTC) +16%. LSI
Seekingalpha · 04/28 16:31
Xbiotech Announces French National Agency Approval And National Cancer Institute Funding To Support Phase I/II/III Clinical Study For Natrunix In Combination With Trifluridine/Tipiracil For Treatment Of Metastatic Colorectal Cancer
XBiotech (NASDAQ:XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de sécurité du médicament et des produits de
Benzinga · 04/28 13:08
XBiotech Says French Regulator Approves Trial of Natrunix Combination Treatment for Colorectal Cancer; Shares Rise
MT Newswires · 04/28 13:06
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in FranceAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health...
GlobeNewswire · 04/28 13:00
XBiotech (NASDAQ:XBIT) shareholders have endured a 48% loss from investing in the stock a year ago
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...
Simply Wall St. · 03/15 15:00
BRIEF-Thorpe Mckenzie Reports 9.81% Passive Stake In Xbiotech Inc As Of December 31, 2021
reuters.com · 02/16 14:55
More
No Data
Learn about the latest financial forecast of XBIT. Analyze the recent business situations of Xbiotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XBIT stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
High18.00
Average18.00
Low18.00
Current 5.47
EPS
Actual
Estimate
-0.17-0.13-0.08-0.04
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 82
Institutional Holdings: 4.28M
% Owned: 14.06%
Shares Outstanding: 30.44M
TypeInstitutionsShares
Increased
22
250.09K
New
12
153.11K
Decreased
13
361.73K
Sold Out
16
530.66K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
John Simard
Chief Scientific Officer
Sushma Shivaswamy
Vice President - Finance/Director of Human Resources/Secretary
Queena Han
Lead Director/Independent Director
Jan-Paul Waldin
Independent Director
Peter Libby
Independent Director
Donald Macadam
Independent Director
W. Thorpe McKenzie
No Data
No Data
About XBIT
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Webull offers kinds of XBiotech Inc stock information, including NASDAQ:XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.